NCT04464759View on ClinicalTrials.gov

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Melanoma
Interventions
DRUG

Nivolumab

Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

DRUG

Hydroxychloroquine

Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

DRUG

Ipilimumab

Combination of nivolumab, hydroxychloroquine and ipilimumab

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ravi Amaravadi, MD

OTHER

NCT04464759 - A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma | Biotech Hunter | Biotech Hunter